Insulet Corporation (PODD)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
Key Insights
Share Price
$236.99Market Cap
$16.62 BillionTotal Outstanding Shares
70.12 Million SharesTotal Employees
3,000Dividend
No dividendIPO Date
May 15, 2007SIC Description
Surgical & Medical Instruments & ApparatusHomepage
https://www.insulet.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
July 1, 2023 to June 30, 2024
| Metric | Value |
|---|---|
| Exchange Gains/Losses | $-1.60 Million |
| Net Cash Flow From Investing Activities, Continuing | $-103.10 Million |
| Net Cash Flow From Operating Activities, Continuing | $285.30 Million |
| Net Cash Flow | $160.90 Million |
| Net Cash Flow From Operating Activities | $285.30 Million |
| Net Cash Flow From Financing Activities, Continuing | $-19.70 Million |
| Net Cash Flow, Continuing | $162.50 Million |
| Net Cash Flow From Investing Activities | $-103.10 Million |
| Net Cash Flow From Financing Activities | $-19.70 Million |
Income Statement
July 1, 2023 to June 30, 2024
| Metric | Value |
|---|---|
| Benefits Costs and Expenses | $1.61 Billion |
| Gross Profit | $1.29 Billion |
| Operating Expenses | $1.02 Billion |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Net Income/Loss Available To Common Stockholders, Basic | $395.30 Million |
| Selling, General, and Administrative Expenses | $815.60 Million |
| Cost Of Revenue | $580.50 Million |
| Operating Income/Loss | $272.70 Million |
| Net Income/Loss | $395.30 Million |
| Revenues | $1.87 Billion |
| Research and Development | $203.90 Million |
| Net Income/Loss Attributable To Parent | $395.30 Million |
| Costs And Expenses | $1.61 Billion |
| Diluted Average Shares | $224.69 Million |
| Basic Average Shares | $209.88 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Income/Loss From Continuing Operations After Tax | $395.30 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Basic Earnings Per Share | $5.65 |
| Income/Loss From Continuing Operations Before Tax | $267.50 Million |
| Diluted Earnings Per Share | $5.53 |
| Income Tax Expense/Benefit | $-127.80 Million |
Balance Sheet
July 1, 2023 to June 30, 2024
| Metric | Value |
|---|---|
| Noncurrent Assets | $1.13 Billion |
| Inventory | $430.90 Million |
| Current Liabilities | $486.00 Million |
| Current Assets | $1.75 Billion |
| Other Current Assets | $1.32 Billion |
| Noncurrent Liabilities | $1.40 Billion |
| Equity | $998.40 Million |
| Accounts Payable | $76.80 Million |
| Assets | $2.88 Billion |
| Liabilities And Equity | $2.88 Billion |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Other Current Liabilities | $409.20 Million |
| Liabilities | $1.88 Billion |
| Equity Attributable To Parent | $998.40 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ2024 Financhle. All Rights Reserved.